Surgical Science Sweden AB, listed on Nasdaq First North Growth Market, has performed a directed new issue of shares valued at approximately SEK 2.7 billion at a subscription price of SEK 210.
The subscription price was established through a so-called accelerated book building procedure arranged by Pareto Securities. The net proceeds from the directed issue of shares will primarily be used to finance the acquisition of Simbionix USA Corp which was made public on the same day as the directed new issue of shares.
Vinge’s team consisted of Anders Strid, Edin Agic (project manager) and Adrian Filipovic.
